PainReform (NASDAQ:PRFX – Get Free Report) and Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.
Analyst Ratings
This is a breakdown of current recommendations and price targets for PainReform and Inhibikase Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
| Inhibikase Therapeutics | 1 | 2 | 4 | 3 | 2.90 |
Inhibikase Therapeutics has a consensus target price of $4.75, indicating a potential upside of 203.51%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than PainReform.
Profitability
This table compares PainReform and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PainReform | N/A | N/A | N/A |
| Inhibikase Therapeutics | N/A | -42.80% | -40.58% |
Institutional and Insider Ownership
37.3% of PainReform shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility & Risk
PainReform has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Valuation & Earnings
This table compares PainReform and Inhibikase Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PainReform | $20,000.00 | 33.28 | -$5.02 million | ($736.66) | -0.00 |
| Inhibikase Therapeutics | $260,000.00 | 839.92 | -$48.26 million | ($0.43) | -3.64 |
PainReform has higher earnings, but lower revenue than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
Summary
Inhibikase Therapeutics beats PainReform on 7 of the 13 factors compared between the two stocks.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.
